In-house IP roundup: UK Actavis ruling raises clarity on dosage regimen patents; how businesses get software patents; Google and Avon reveal portfolio management strategies

Innovator and generics businesses say that the UK Supreme Court’s ruling in Actavis v Icos and the guidelines it produced give them greater insight into whether a dosage regimen would be considered obvious. Read more ...

Counsel at Amadeus, IBM, a tech company and a bank reveal how they give themselves the best chance of getting software patent protection through better communication with engineers and storytelling with patent examiners. Read more ... 

Senior patent counsel at one of the world’s biggest makeup companies and a tech giant delve into their sometimes cut-throat tactics for shaping their patent portfolios and the cost-saving drivers behind them. Read more ... 

In-house lawyers from Citigroup, Nevro and Etsy share their thoughts on blockchain strategies and how registrations might be disrupted by eligibility issues. Read more ... 

Sign up to receive more content like this in Patent Strategy’s weekly newsletter.